HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma

Area of Science:

• Immunotherapy
• Oncology
• Cancer Research

Background:

• Adoptive cell therapy (ACT) using NY-ESO-1-specific T cells shows promise for soft tissue sarcoma (STS) but offers limited tumor control.
• Modulating NY-ESO-1 expression with histone deacetylase inhibitors (HDACis) is a potential strategy to improve ACT efficacy.

Purpose of the Study:

• To investigate the ex vivo efficacy of combining NY-ESO-1-specific T cells with panobinostat or vorinostat (HDACis) for STS treatment.
• To assess the impact of HDACi pretreatment on STS cell sensitivity, NY-ESO-1 expression, and T cell response.

Main Methods:

• Treatment of NY-ESO-1-positive STS cell line SW982 with panobinostat or vorinostat.
• Co-culture of HDACi-treated STS cells with NY-ESO-1-specific T cells.
• Analysis of STS cell lysis, NY-ESO-1 and HLA-ABC expression, and T cell activation markers (CD25, cytokine release).

Main Results:

• STS cells demonstrated sensitivity to HDACis.
• HDACi pretreatment enhanced the cytotoxic lysis of SW982 cells by NY-ESO-1-specific T cells.
• HDACi treatment increased NY-ESO-1 and HLA-ABC expression on SW982 cells and CD25 expression on T cells.
• HDACis augmented the immune reactivity and cytokine release of NY-ESO-1-specific CD8+ T cells.

Conclusions:

• Pretreatment with HDACis can enhance the cytotoxic efficacy of NY-ESO-1-specific T cells against NY-ESO-1-positive STS.
• Combining HDACis with NY-ESO-1-specific T cell therapy is a promising strategy for improving treatment outcomes in STS.
• This approach warrants further investigation for clinical application in soft tissue sarcoma.